Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India · Delayed Price · Currency is INR | Market Cap | 262.53B |
| Revenue (ttm) | 25.29B |
| Net Income (ttm) | 5.13B |
| Shares Out | 83.55M |
| EPS (ttm) | 61.49 |
| PE Ratio | 51.10 |
| Forward PE | 49.33 |
| Dividend | 28.00 (0.89%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 98,609 |
| Average Volume | 150,089 |
| Open | 3,130.00 |
| Previous Close | 3,208.10 |
| Day's Range | 3,083.00 - 3,165.50 |
| 52-Week Range | 2,293.55 - 3,540.00 |
| Beta | 0.05 |
| RSI | 49.82 |
| Earnings Date | Oct 31, 2025 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In 2024, Dr. Lal PathLabs's revenue was 24.61 billion, an increase of 10.54% compared to the previous year's 22.27 billion. Earnings were 4.87 billion, an increase of 36.17%.
Financial StatementsNews
Dr. Lal PathLabs Ltd (BOM:539524) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Dr. Lal PathLabs Ltd (BOM:539524) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
Q2 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Q2 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q2 2026 Earnings Report Preview: What To Expect
Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market
Shares of diagnostic service providers Dr Lal PathLabs and Metropolis Healthcare slipped in Monday’s trade following Amazon India’s announcement of its foray into the diagnostics space. Amazon launche...
Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests
Shares of Dr Lal PathLabs fell over 2% to Rs 2,849.00 on Monday after Amazon India announced the launch of its diagnostics service in collaboration with Orange Health Labs. The new offering is expecte...
Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY
Dr. Lal PathLabs Ltd reported a strong financial performance for the fourth quarter ended March 31, 2025, with consolidated net profit rising 81% year-on-year to ₹155.5 crore, up from ₹85.8 crore in Q...
Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls
Shares of Dr Lal Path Labs surged by 3.46%, rising ₹112.75 to trade at ₹3,368.45 on the NSE at 9:16 AM. The stock’s upward movement follows the release of strong Q2 FY25 earnings and positive brokerag...
Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying
Several brokerages have shared their views on Dr Lal Path Labs. Here’s what they are saying: Goldman Sachs: Goldman Sachs has maintained its sell call on Dr Lal Path and raised the share price target ...
UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price
UBS has maintained its buy rating on Dr LalPath Labs, with a share price target of ₹3,500, indicating a 7.7% upside from the current market price (CMP). The company’s Q2 performance was robust, showin...
Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore
Dr Lal PathLabs has reported solid financial results for Q2 FY25, showing notable growth in both revenue and net profit on a year-on-year (YoY) basis. Key Financial Highlights: Revenue for Q2 FY25 sto...
Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720
Nomura has maintained its ‘Buy’ rating on Dr Lal PathLabs, setting a target price of ₹3,720, which implies a potential upside from the current market price of ₹3,280. Nomura expects steady performance...